Immunocore Limited

4 trials 3 recruiting Commercial sponsor

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

3 Recruiting

1 Completed trials

7 Countries active

9 Unique IMPs

100% Results reported

Phase II/III

Phase II

Phase I

Phase I (FiH)

Phase II/III: 1 Phase II: 1 Phase I: 1 Phase I (FiH): 1

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Malignant melanoma 2 Non-small cell lung cancer 1 Synovial sarcoma 1 Adenoid cystic carcinoma 1 Endometrial sarcoma 1 Metastatic malignant melanoma 1 Small cell lung cancer 1 Endometrial cancer 1 Papillary serous endometrial carcinoma 1 Uveal melanoma 1 Clear cell endometrial carcinoma 1 Ovarian cancer 1

Top IMPs

PEMBROLIZUMAB 2 TEBENTAFUSP 2 BISPECIFIC PROTEIN WITH A HIGH-AFFINITY T-CELL RECEPTOR DOMAIN FUSED TO AN ANTIBODY SINGLE-CHAIN VARIABLE FRAGMENT AGAINST CD3 1 IPILIMUMAB 1

All trials

4 total

Phase 1 Study of IMC-P115C in Advanced PRAME Positive Cancers Recruiting

2023-509767-25-00 Phase I 3 countries
Tebentafusp Regimen Versus Investigator’s Choice in Previously Treated Advanced Melanoma (TEBE-AM) Recruiting

2022-502732-39-00 Phase II/III 7 countries PEMBROLIZUMAB; TEBENTAFUSP
Phase 1/2 study of IMC-M113V in virologically suppressed chronic HIV infection Recruiting

2024-513938-38-00 Phase I (FiH) 2 countries BISPECIFIC PROTEIN WITH A HIGH-AFFINITY T-CELL RECEPTOR DOMAIN FUSED TO AN ANTIB…
Safety and efficacy of IMCgp100 versus Investigator’s Choice in advanced uveal melanoma Ended

2024-517290-24-00 Phase II 5 countries IPILIMUMAB; PEMBROLIZUMAB; TEBENTAFUSP

Showing 1–4 of 4 trials

← All sponsors A–Z